Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Background:
- Lymphangioleiomyomatosis (LAM) is a rare type of lung disease that occurs almost
exclusively in women. In LAM, muscle tissue grows in the lungs and starts to block the flow
of air. It is a progressive disease, and in severe cases may require a lung transplant. One
possible treatment to improve breathing in people with LAM is inhaled albuterol. Albuterol
can be given in a metered dose inhaler (MDI) or with a nebulizer. Researchers want to compare
these methods to see which method best improves lung function in women with LAM.
Objectives:
- To see whether a nebulizer or MDI can better improve lung function in women with LAM.
Eligibility:
- Women at least 18 years of age who have impaired lung function because of LAM.
Design:
- Participants will be screened with a physical exam and medical history. No lab tests
will be needed for this study.
- Participants will have a 3-day overnight stay at the National Institutes of Health.
Those who are using long-acting inhalers will have to stop taking these drugs 1 week
before the study.
- Participants will receive either the nebulizer or two or four puffs of the inhaler. Four
puffs of albuterol is a higher dose than is normally prescribed, and is being tested on
this study.
- Participants will have each treatment around the same time of day on each of the 3 days.
Before and after taking the albuterol, participants will have lung function tests.